Biovica's blood test provides new answers for cancer care
Cancer diagnostics is facing a shift that could have a major impact on both healthcare practices and treatment outcomes – and Biovica...
Green light for PHI to step up its commercial strategy
Phase Holographic Imaging (PHI) has now formally decided...
Enzymatica's CEO comments on his resignation
Claus Egstrand leaves the role as CEO of Enzymatica...
BioStock Global Forum 2025 – watch the videos
Rights issue strengthens AlzeCure's position
AlzeCure Pharma is conducting a rights issue of SEK 48,5 million,...
AI-designed proteins are created in seconds
Australian researchers have used artificial intelligence...
The price of Leqembi needs to be lowered in Japan
A new analysis from Japan's Center for Outcomes...
Merck gears up in lung diseases with giant acquisition
American pharmaceutical giant Merck announced on Wednesday that...
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AstraZeneca's rare disease subsidiary, Alexion, has entered into...
AlzeCure Pharma: “We have good momentum”
AlzeCure Pharma, which develops small molecule drugs for the treatment of...
Trump threatens 200 percent tariffs on pharmaceuticals
At a cabinet meeting on Tuesday, the US President announced...
New announcement from Japan strengthens Medivir's patent portfolio
The Japanese Patent Office has issued a Notice of...
BioStock Investor Pitch: AlzeCure Pharma
Swedish AlzeCure Pharma develops small molecule drug candidates for the treatment of...
In the shadow of the GLP-1 hype: new report criticizes pharmaceutical companies' patent strategies
A new report from the patent organization I-MAK sheds light...
Five Nordic biotech stock market winners in H1 2025
Vacation times are approaching and when 2025 is now...
Chugai and Gero in billion-dollar deal within AI
Chugai Pharmaceutical and Gero have entered into a joint...
AlzeCure's CEO: "Increased interest after EIC grant and FDA feedback"
Today marks the start of the subscription period for AlzeCure Pharma's rights issue,...
Karolinska Development's partner cancels development
Karolinska Development recently announced that its partner Organon has decided...
Cereno Scientific signs agreement with CRO for phase IIb study
Cereno Scientific has taken an important step towards...
Klaria Pharma's CEO comments on the ongoing capital raising
Klaria Pharma is about to take the next...
Sobi and Apellis update royalty agreement for Aspaveli
Sobi has entered into a new agreement with Apellis...
Alligator presents promising 24-month data at ESMO GI 2025
Alligator Bioscience announces that new data from the...
Hansa Biopharma comments on five-year results for imlifidase
Hansa Biopharma presented promising five-year data from...
AbbVie acquires Capstan Therapeutics for up to $2,1 billion
The deal gives AbbVie access to a method for...
Bridgepoint steps into Safe Life
Private Equity company Bridgepoint has signed an agreement to...
Notes
Cantargia publishes data for nadunolimab in lung cancer
Genmab reports sales of DARZALEX
AlzeCure receives additional subscription commitments of SEK 7 million
AstraZeneca updates on phase III study
Orexo maintains full-year forecast despite currency headwinds
NEWSLETTER
Premium
Cinclus Pharma signs billion-dollar deal with Zentiva
Drug tariffs could increase costs by $51 billion
AstraZeneca in new AI investment
Extensive study points to cannabis' potential in cancer
Eli Lilly's oral weight loss drug impresses in Phase III
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Upcoming events
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...